KR20230152257A - Composition for skin whitening comprising biorenovation extract of Lycium chinense leaf as effective component - Google Patents

Abstract

The present invention relates to a composition for skin whitening containing a bioconversion extract of Goji berry leaves as an active ingredient. Specifically, the bioconversion extract of Goji berry leaves prepared through a bioconversion method has no cytotoxicity, and is not cytotoxic compared to the Goji berry leaf extract. Since it has an excellent effect of inhibiting the production of melanin and the activity of tyrosinase, it can be usefully used as a functional cosmetic for skin whitening, a food that can prevent or improve skin pigmentation diseases, or a treatment.

Description

A composition for skin whitening comprising biorenovation extract of Lycium chinense leaf as an effective component}

The present invention relates to a composition for skin whitening containing bioconversion extract of Goji berry leaves as an active ingredient.

The skin is one of the body tissues directly exposed to the external environment, and acts as a barrier between the internal and external environment of the human body, protecting the living body from the surrounding environment by preventing the invasion of external environmental pollutants and microorganisms, including chemicals and ultraviolet rays. . Additionally, the color of the skin is determined by melanin, hemoglobin, and carotene, of which melanin plays the most important role. In addition to determining a person's skin color, melanin also performs skin protection functions such as absorbing ultraviolet rays and acting as a free radical scavenger. However, when melanin is excessively produced due to external environmental changes such as overexposure to ultraviolet rays, air pollution, stress, etc., pigmentation occurs within the skin, causing melanism, spots, and freckles. Darkening of the skin occurs due to the reaction of skin cells to internal and external factors, the representative factor being exposure to ultraviolet rays. That is, when the skin is exposed to ultraviolet rays, tyrosinase is activated. Through an oxidation process, the tyrosinase acts on tyrosine present in skin tissue to produce DOPA and dopaquinone, A polymer called melanin is synthesized in melanosomes within melanocytes, which are skin pigment cells. This melanin is transferred to keratinocytes, which are keratin forming cells of the skin, and reaches the skin surface through the keratinization process. It protects the skin from ultraviolet rays. Therefore, melanin is an essential ultraviolet ray protection agent for our human body, and also plays the role of an effective free radical scavenger that removes various radicals that modify biological components such as proteins, lipids, and nucleic acids. However, when melanin is synthesized excessively locally or when the physiological function of the skin deteriorates due to skin lesions or aging, melanin is deposited on the skin surface, causing spots, freckles, and various pigmentation. As the cause and mechanism of skin darkening have been revealed as described above, in the production of whitening cosmetics, substances that have the effect of inhibiting the activity of tyrosinase, an enzyme involved in the skin darkening process, are mixed into cosmetics or some reactions during the melanin production process are used. Methods of reducing melanin production by inhibiting are commonly used.

Commonly known whitening ingredients include substances that inhibit tyrosinase enzyme activity such as kojic acid and arbutin, hydroquinone, L-ascorbic acid and their derivatives, and various There are plant extracts. By inhibiting the synthesis of melanin pigment, they can not only brighten skin tone and achieve skin whitening, but also improve skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics. However, when applied to the skin, there is a limit to the amount of use due to safety issues such as irritation and redness, or the effect is so small that no practical effect can be expected. Therefore, there is an urgent need to develop a material that is safe for the living body, has stable active ingredients, and, above all, has an excellent whitening effect.

Biorenovation refers to a method of producing or manufacturing a desired product from precursor materials using the enzymatic function of microorganisms, and is a method of inducing structural changes in materials through biological methods such as microbial fermentation or enzyme treatment. collectively referred to as It is newly known that due to the above changes, the content of active ingredients is increased, absorption rate is improved, and new functional ingredients are created, and the development of materials using these techniques is attracting attention around the world.

Meanwhile, Lycium chinense Miller is a woody plant of the genus Lycium chinense of the Solanaceae family and is a herbal medicine that grows or is cultivated in Korea, China, Taiwan, Japan, and Europe. The fruits, leaves, and roots of goji berry are used in different parts, and the fruits, leaves, and roots of goji berry have functional properties such as betaine, rutin, kukoamine A, and -sitosterol. Contains a large amount of ingredients.

As for prior art related to skin whitening, Korean Patent No. 2111648 discloses ‘Manufacturing method of Yoshino cherry leaf bioconversion extract and cosmetic composition containing the same for skin whitening’, and Korean Patent No. 2371360 discloses ‘Honey, Schisandra chinensis. , a cosmetic composition with whitening and moisturizing effects containing a mixed extract of goji berry and green tea far-infrared rays as an active ingredient' is disclosed. However, the 'composition for skin whitening containing bioconverted extract of Goji berry leaves as an active ingredient' of the present invention has not yet been disclosed.

The present invention was developed in response to the above-mentioned needs. The present invention provides a composition for skin whitening containing a bioconversion extract of Goji berry leaves as an active ingredient, and the bioconversion extract of Goji berry leaves prepared through a bioconversion method. The present invention was completed by confirming that it is not cytotoxic and has a significant effect of inhibiting melanin production and tyrosinase activity compared to Goji berry leaf extract.

In order to solve the above problems, the present invention provides a cosmetic composition for skin whitening containing bioconversion extract of Wolfberry leaves as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating melanin hyperpigmentation disease containing a bioconverted extract of Goji berry leaves as an active ingredient.

In addition, the present invention provides a health functional food composition for preventing or improving melanin hyperpigmentation disease containing a bioconverted extract of Goji berry leaves as an active ingredient.

The present invention relates to a composition for skin whitening containing a bioconversion extract of Goji berry leaves as an active ingredient. Specifically, the bioconversion extract of Goji berry leaves prepared through a bioconversion method has no cytotoxicity, and is not cytotoxic compared to the Goji berry leaf extract. Therefore, it is effective in suppressing the production of melanin and the activity of tyrosinase.

Figure 1 shows the results of confirming cell viability when B16F10 cells were treated with biotransformation extracts of Wolfberry leaves according to different concentrations according to an embodiment of the present invention. LC is a group treated with Goji berry leaf extract, LCBR is a group treated with a bioconversion extract of Goji berry leaves, and BJ is a group treated with a suspension of the Bacillus sp. JD3-7 strain.
Figure 2 shows the results of measuring the melanin content when B16F10 cells were treated with α-MSH (α-melanocyte stimulating hormone) and biotransformed extract of Goji berry leaves at different concentrations according to an embodiment of the present invention. LCBR is a group treated with bioconversion extract of Goji berry leaves, and BJ is a group treated with suspension of Bacillus sp. JD3-7 strain. ** indicates a statistically significant decrease in the melanin content of the group treated with the bioconverted extract of Goji berry leaves (LCBR) of the present invention compared to the group treated with α-MSH alone, p<0.01.
Figure 3 shows the results of measuring tyrosinase activity when B16F10 cells were treated with α-MSH (α-melanocyte stimulating hormone) and biotransformation extract of Goji berry leaves at different concentrations according to an embodiment of the present invention. LCBR is a group treated with bioconversion extract of Goji berry leaves, and BJ is a group treated with suspension of Bacillus sp. JD3-7 strain. ** indicates a statistically significant decrease in tyrosinase activity of the group treated with the bioconverted extract of Goji berry leaves (LCBR) of the present invention compared to the group treated only with α-MSH, p<0.01.

In order to achieve the object of the present invention, the present invention provides a cosmetic composition for skin whitening containing bioconversion extract of Wolfberry leaves as an active ingredient.

The term "bioconversion" or "bioconversion method" used in the present invention refers to a method of producing and manufacturing a compound that induces structural changes such as phosphorylation and glycosylation from a substrate or precursor using microorganisms. means. The phosphorylation means binding to the substrate by replacing a phosphoric acid group (HOPO(OH)O-) with the hydrogen atom of the substrate by the action of a phosphorylation enzyme, and the glycosylation involves binding to the substrate as a monosaccharide, This means that glucosides such as polysaccharides are added.

The bioconversion extract of Wolfberry leaves can be prepared by mixing microorganisms with Wolfberry leaf extract to induce a bioconversion reaction, preferably by a method comprising the following steps, but is not limited to this:

(1) Extracting by adding an extraction solvent to Goji berry leaves;

(2) filtering and concentrating the extract of step (1) under reduced pressure;

(3) mixing the extract concentrated under reduced pressure in step (2) with microorganisms to induce a bioconversion reaction;

(4) Obtaining a supernatant after centrifuging the bioconversion reactant of step (3).

In step (1), the extraction solvent is preferably selected from water, lower alcohols of C ₁ to C ₄ , or mixtures thereof, more preferably water, but is not limited thereto. In step (3), the microorganism may preferably be a Bacillus sp. strain, more preferably a Bacillus sp. JD3-7 strain, but is not limited thereto.

The composition has the characteristic of inhibiting the production of melanin or the activity of tyrosinase.

On the other hand, the whitening effect refers to the effect of improving or preventing dark skin, spots, freckles, and dark circles caused by various factors such as exposure to ultraviolet rays, changes in hormonal balance, and genetic programs, and making the skin transparent and beautiful. Alternatively, it is intended to have the effect of maintaining transparent and beautiful skin, reducing dullness of the skin, and increasing luster and tightness, etc. In general, it is known that dark skin, spots, freckles, and dark circles occur when melanocytes are stimulated by ultraviolet rays or changes in hormonal balance, and biosynthesized melanin pigment is deposited on the skin. Therefore, if the production of melanin can be suppressed, it is possible to prevent and improve dark skin, freckles, freckles, and dark circles.

The cosmetic composition of the present invention is prepared in a formulation selected from solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray. It is desirable to be

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene. There are glycols, 1,3-butylglycol oil, fatty esters of glycerol, fatty acid esters of polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, the carrier component includes water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.

When the formulation of the cosmetic composition of the present invention is a paste, cream, or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide are used as carrier ingredients. etc. can be used.

When the formulation of the cosmetic composition of the present invention is powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, when the cosmetic composition is a spray, chlorofluorohydride may be used as a carrier ingredient. It may contain propellants such as carbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyl taurate, and sarcosinate. , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.

In addition to the active ingredients, the cosmetic composition of the present invention may further contain one or more skin whitening active ingredients that exhibit the same or similar functions. Skin whitening active ingredients include kojic acid and its derivatives, arbutin, ascorbic acid and its derivatives, hydroquinone and its derivatives, resorcinol, cycloalkanone, methylenedioxyphenyl alkanol, 2,7-dinitroindazole, or These include, but are not limited to, plant extracts such as tangerine extract, rice extract, and licorice extract.

The cosmetic composition of the present invention may further contain excipients including fluorescent substances, fungicides, hydrotropes-inducing substances, moisturizers, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, sunscreens, vitamins, plant extracts, etc. .

In addition, the present invention provides a pharmaceutical composition for preventing or treating melanin hyperpigmentation disease containing a bioconverted extract of Goji berry leaves as an active ingredient.

The term “hyperpigmentation” used in the present invention means that a specific area of the skin or hands or toenails becomes black or dark compared to other areas due to an excessive increase in melanin. The melanin hyperpigmentation disease includes freckles; senile spots; liver spots; freckles; brown or black spots; solar pigment spots; cyanic melasma; Hyperpigmentation after drug use; gravidic chloasma; and hyperpigmentation due to inflammation or dermatitis due to wounds; Any one selected from among them is preferred, but is not limited thereto.

The composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents in addition to the above active ingredients, and may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc. These solid preparations contain one or more compounds and at least one excipient, such as starch, calcium carbonate, sucrose, or lactose ( It is prepared by mixing lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate, talc, etc. are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, aerosols, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspension solvents may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurel, glycero gelatin, etc. can be used. When administering parenterally, it is preferable to choose external dermal application or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dura, or intracerebrovascular injection.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of the effective amount is determined by the type, severity, and activity of the patient's disease. , can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

The dosage of the composition of the present invention varies depending on the patient's weight, age, gender, health condition, diet, administration time, administration method, excretion rate, and severity of disease. The composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, and methods using biological response modifiers.

In addition, the present invention provides a health functional food composition for preventing or improving melanin hyperpigmentation disease containing a bioconverted extract of Goji berry leaves as an active ingredient.

The health functional food composition for preventing or improving melanin hyperpigmentation disease of the present invention is preferably manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

When using the health functional food composition of the present invention as a food additive, the biotransformation extract of Goji berry leaves can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention or improvement). Generally, when producing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw materials. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There are no special restrictions on the types of foods above. Examples of foods to which the extract can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, These include alcoholic beverages and vitamin complexes, and include all health functional foods in the conventional sense.

When the composition of the present invention is used as a health drink, it may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional drinks. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumarin and stevia extract or synthetic sweeteners such as saccharin or aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention. The composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal neutralizer, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonic acid. It may contain carbonating agents used in beverages. Additionally, the composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

Hereinafter, the present invention will be described in detail through examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.

[Materials and Methods]

1. Extract preparation

Dried and crushed goji berries ( Lycium chinense ) 500 ml of distilled water was added to 1 g of leaves, extraction was repeated twice for 24 hours at 70°C, the recovered primary and secondary extracts were mixed and filtered through a filter (TOYO, Japan) with a pore size of 5.0 ㎛. An extract was obtained. Afterwards, twice the amount of ethyl acetate was added to the filtered extract to fractionate it, and then the recovered ethyl acetate layer was concentrated under reduced pressure to prepare a sample (Goji berry leaf extract).

2. Microbial culture and bioconversion reaction

The microorganism for biorenovation was the Bacillus JD3-7 ( Bacillus sp. JD3-7, KACC 92346P) strain isolated from traditional soybean sauce from Jeju Island, and incubated at 30°C for 18 hours using LB liquid medium. cultured for a while. Afterwards, the cells recovered by centrifugation at 4,000 rpm for 15 minutes were washed twice and suspended in 100 ml of PG buffer (50 mM Phosphate buffer, 2% Glycerin). Bacillus JD3-7 cells were suspended without adding a substrate. A control group (BJ) and an experimental group (LCBR) flask in which Bacillus JD3-7 cells were added to 100 mg of Goji berry leaf extract were biotransformed under the same conditions at 30°C for 72 hours. After completion of the reaction, the pellet and supernatant were separated by centrifugation, and the supernatant from which the pellet was removed (hereinafter referred to as 'bioconversion extract of Wolfberry leaves') was freeze-dried at -110°C and used in the experiment.

3. Experimental materials and cell culture

α-MSH (α-melanocyte stimulating hormone) and L-DOPA (L-3,4-dihydroxyphenylalanin) were purchased from Sigma-Aldrich (St. Louis, MO, USA), and B16F10 melanoma cells were purchased from ATCC (American). It was purchased and used from Type Cell Culture, USA. B16F10 cells were grown using DMEM (Dulbecco's Modified Eagle Medium, Gibco, Grand Island, NY, USA) medium containing 100 units/ml of penicillin-streptomycin and 10% FBS (fetal bovine serum) at 37°C and 5% CO. ₂ It was cultured in an incubator, subcultured every 3 days to stabilize it, and then used in experiments.

4. Cytotoxicity

The cytotoxicity of the biotransformation extract of Goji berry leaves against B16F10 cells was measured through cell viability analysis using the MTT assay. The cells were distributed in a 24 ^- well plate at a concentration of 1.0 Afterwards, MTT (Thiazolyl Blue Tetrazolium Blue) reagent was added to each well and reacted for 4 hours. DMSO was added to dissolve the formazan blue formed in each well, and the absorbance was measured at 570 nm using an ELISA reader. was measured.

5. Melanin production inhibition activity

B16F10 cells (4.0×10 ⁴ cells/well) were pre-cultured for 24 hours, then treated with biotransformation extract of Wolfberry leaves and α-MSH (200nM) simultaneously and cultured for 72 hours. Afterwards, the cells were washed once with PBS buffer (Sigma-Aldrich, St. Louis, MO, USA) and recovered by treatment with 0.5% trypsin-EDTA (Gibco, Grand Island, NY, USA). The recovered cells were incubated at 800 rpm. Centrifuged for 3 minutes. To the pellet from which the supernatant was removed, 100 ㎕ of RIPA (radioimmunoprecipitation assay) buffer (Sigma-Aldrich, St. Louis, MO, USA) containing 1% protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA) was added. Afterwards, it was dissolved with a lysis buffer for 1 hour and then centrifuged at 13,000 rpm for 30 minutes to separate the pellet. Afterwards, 500㎕ of 1N NaOH (10% DMSO) was added to the pellet and heated at 90°C for 1 hour, then transferred to a 96-well plate and the absorbance was measured at 405nm.

6. Tyrosinase production inhibitory activity

B16F10 cells (4.0×10 ⁴ cells/well) were cultured for 24 hours, then treated with biotransformation extract of Goji berry leaves and α-MSH (200nM) simultaneously and cultured for 72 hours. Afterwards, the cells were lysed with lysis buffer for 1 hour, centrifuged to separate the protein supernatant, and the protein in the recovered supernatant was quantified using a BCA kit (Bio-Rad, USA). L-DOPA was added to the quantified protein, reacted in the dark for 2 hours, and then the absorbance was measured at 490 nm.

7. Statistical processing

All experiments were repeated three times and the results were expressed as mean ± standard deviation. Statistical analysis was performed using analysis of variance (ANOVA) followed by multiple comparisons using student's t-test to verify the significance ( p <0.01) of each treatment section.

Example 1. Cell viability analysis

MTT analysis was performed to confirm the cytotoxicity of the biotransformation extract of Wolfberry leaves, the Wolfberry leaf extract, and the Bacillus JD3-7 strain suspension of the present invention in B16F10 cells induced by α-MSH. As a result of confirming the cell viability by treating each sample at concentrations of 50, 100, and 200㎍/㎖, as shown in Figure 1, the cell viability of the biotransformation extract (LCBR) of Goji berry leaves of the present invention was maintained at all treatment concentrations. , Bacillus JD3-7 strain suspension (BJ) also showed a cell survival rate of more than 90%. On the other hand, Goji berry leaf extract (LC) showed cytotoxicity in a concentration-dependent manner.

Example 2. Melanin synthesis inhibition effect

The inhibitory effect on melanin synthesis of the biotransformed extract of Goji berry leaves of the present invention was confirmed in B16F10 cells induced by α-MSH.

As a result, as shown in Figure 2, it was confirmed that the melanin synthesis inhibitory effect in the group treated with the bioconverted extract of Goji berry leaves (LCBR) was statistically significantly reduced compared to the group treated with α-MSH alone.

Example 3. Tyrosinase activity inhibition effect

The inhibitory effect on tyrosinase activity of the biotransformed extract of Goji berry leaves of the present invention was confirmed in B16F10 cells induced by α-MSH.

As a result, as shown in Figure 3, it was confirmed that the inhibitory effect on tyrosinase activity in the group treated with bioconverted extract of Goji berry leaves (LCBR) was statistically significantly reduced compared to the group treated with α-MSH alone.

Claims (8)

A cosmetic composition for skin whitening containing bioconversion extract of Goji berry leaves as an active ingredient. The cosmetic composition for skin whitening according to claim 1, wherein the bioconversion extract of Goji berry leaves is prepared by mixing microorganisms with the Goji berry leaf extract to induce a bioconversion reaction. The cosmetic composition for skin whitening according to claim 2, wherein the microorganism is a Bacillus sp. strain. The cosmetic composition for skin whitening according to claim 2, wherein the extract is extracted using water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The cosmetic composition according to claim 1, wherein the cosmetic composition is selected from solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing agents, oils, powder foundations, emulsion foundations, wax foundations and sprays. A cosmetic composition for skin whitening, characterized in that it is manufactured in a formulation that is. A pharmaceutical composition for preventing or treating melanin hyperpigmentation disease containing a bioconverted extract of Goji berry leaves as an active ingredient. The method of claim 6, wherein the melanin hyperpigmentation disease includes freckles, senile spots, liver spots, melasma, brown or dark spots, solar pigmentation spots, cyanic melasma, hyperpigmentation after drug use, and pregnancy brown spots. Chloasma), or a pharmaceutical composition for the prevention or treatment of melanin hyperpigmentation disease, characterized as hyperpigmentation after inflammation caused by wounds or dermatitis, including scratches and burns. A health functional food composition for preventing or improving melanin hyperpigmentation disease containing bioconversion extract of Goji berry leaves as an active ingredient.